文献速递头颈部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

PULSAR联合免疫检查点抑制用于儿童转移性黑色素瘤巩固治疗

Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma.
PubMed 文献 · Radiat Oncol · 2025-08-21

本文报告一例源于头颈部的广泛 bulky 儿童转移性黑色素瘤,经抗PD-1联合抗CTLA-4双免疫检查点阻断后快速进展,改用另一种抗PD-1联合酪氨酸激酶抑制剂及PULSAR巩固局部治疗后获得肿瘤缓解和无进展状态1年,随后纵隔新发进展站点接受挽救性PULSAR后再次缓解和无进展6个月。所有较大体积 gross 病灶在联合治疗后均未出现局部进展。提示PULSAR与抗PD-1免疫治疗协同对儿童复发或难治性转移性黑色素瘤有效。

要点

  • 儿童头颈部来源广泛bulky转移性黑色素瘤双免疫检查点阻断后快速进展。
  • 抗PD-1联合TKI及PULSAR巩固治疗后肿瘤缓解、无进展1年。
  • 纵隔新发进展站点行挽救性PULSAR后再次缓解、无进展6个月。

核心结论

  • PULSAR与抗PD-1免疫治疗的协同效应对儿童复发或难治性转移性黑色素瘤有效。

研究设计与样本

  • 本文为单例儿童转移性黑色素瘤病例报告,非临床试验,临床试验编号不适用。

主要发现

  • 患者经抗PD-1联合抗CTLA-4双免疫检查点阻断后快速出现疾病进展。
  • 改用另一种抗PD-1联合酪氨酸激酶抑制剂及PULSAR巩固局部治疗后,获得肿瘤缓解和无进展状态1年。
  • 随后纵隔另一站点进展,继续单药抗PD-1并予挽救性PULSAR,再次获得肿瘤缓解和无进展状态6个月。
  • 所有较大体积 gross 病灶在联合治疗后均未出现局部进展。

临床怎么用

  • 对儿童复发或难治性转移性黑色素瘤,可考虑抗PD-1免疫治疗联合PULSAR巩固局部治疗。
  • 对联合治疗后新发进展站点,可考虑继续免疫治疗并予挽救性PULSAR。

局限性

  • 本文为单例病例报告,证据等级有限,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a case of extensive and bulky pediatric metastatic melanoma originating in the head and neck which markedly responded to combination therapy with anti-programmed cell death (PD-1) inhibition and consolidative personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR). After surgical debulking with neck dissection, the patient was initially treated with anti-PD-1 and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) dual checkpoint blockade immunotherapy, but quickly had disease progression. He was transitioned to a different anti-PD-1 immunotherapy in combination with tyrosine kinase inhibitors in conjunction with consolidative local therapy using PULSAR. This combination therapy achieved tumor response and progression-free status for one year before further disease progression at a separate site in the mediastinum. Due to otherwise good disease control, single agent anti-PD-1 immunotherapy was continued and salvage PULSAR was administered to the progressive site, again resulting in tumor response and progression-free status for 6 months. None of the bulkier sites of gross disease had local progression after combination therapy. This case suggests that the synergistic effect of PULSAR and anti-PD-1 immunotherapy is efficacious for relapsed or refractory metastatic melanoma in pediatric patients. Clinical trial number: not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. McCarty KL, Watt T, Dan TD, et al. Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma. Radiat Oncol. 2025. PMID: 40841670. doi:10.1186/s13014-025-02691-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。